Literature DB >> 23496059

Expression and functional significance of the erythropoietin receptor in hepatocellular carcinoma.

Milljae Shin1, Doopyo Hong, Zhengyun Zhang, You Min Kim, Wookjong Lee, Jae-Won Joh, Sung-Joo Kim.   

Abstract

BACKGROUND: Erythropoietin, through its specific receptor (EpoR), may induce responses in a variety of non-haematopoietic tissues including malignant cells. The purpose of this study was to examine the expression of EpoR in hepatocellular carcinoma (HCC) and to correlate the levels of EpoR expression with the clinicopathological properties of HCC and tumour recurrence.
METHODS: The study included 134 patients who underwent curative hepatectomy for hepatitis B virus (HBV)-related primary HCC. The clinical, laboratory and pathological data from these patients were retrospectively collected. The expression of EpoR mRNA and protein were evaluated by reverse transcription-polymerase chain reaction (RT-PCR) and Western blot analysis, respectively.
RESULTS: Expression of EpoR mRNA in the cirrhotic liver was positively correlated with tumour cell differentiation and 1-year disease-free survival (74.8% in the high expression group versus 46.9% in the low expression group; P = 0.001), as it was for EpoR mRNA expression in HCC (64.4% in the high expression group versus 52.7% in the low expression group; P = 0.044). Tumour recurrence showed stronger dependence on the expression of EpoR protein in non-malignant cirrhotic livers than in HCC.
CONCLUSION: In HBV-related HCC, the levels of EpoR mRNA and protein in non-tumour cirrhotic livers were positively correlated with tumour cell differentiation, which is a favourable predictor of disease-specific survival.
© 2013 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23496059      PMCID: PMC3843615          DOI: 10.1111/hpb.12076

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  38 in total

1.  Erythropoietin receptor expression in human melanoma cells.

Authors:  E Selzer; V Wacheck; R Kodym; H Schlagbauer-Wadl; W Schlegel; H Pehamberger; B Jansen
Journal:  Melanoma Res       Date:  2000-10       Impact factor: 3.599

2.  Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models.

Authors:  M Mittelman; D Neumann; A Peled; P Kanter; N Haran-Ghera
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

3.  The effect of human recombinant erythropoietin on the growth of a human neuroblastoma cell line.

Authors:  Y Wollman; G Westphal; M Blum; R Simantov; S Blumberg; G Peer; T Chernihovsky; E Friedrich; A Iaina
Journal:  Life Sci       Date:  1996       Impact factor: 5.037

4.  Erythropoietin as an angiogenic factor in gastric carcinoma.

Authors:  D Ribatti; A Marzullo; B Nico; E Crivellato; R Ria; A Vacca
Journal:  Histopathology       Date:  2003-03       Impact factor: 5.087

5.  Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma.

Authors:  Geza Acs; Paul J Zhang; Timothy R Rebbeck; Peter Acs; Ajay Verma
Journal:  Cancer       Date:  2002-09-01       Impact factor: 6.860

6.  Analysis of expression of erythropoietin-binding sites in human lung carcinoma by the biotinylated ligand.

Authors:  K Kayser; H J Gabius
Journal:  Zentralbl Pathol       Date:  1992-09

7.  Functional significance of erythropoietin receptor expression in breast cancer.

Authors:  Murat O Arcasoy; Khalid Amin; Aysen F Karayal; Shu-Chuan Chou; James A Raleigh; Mahesh A Varia; Zishan A Haroon
Journal:  Lab Invest       Date:  2002-07       Impact factor: 5.662

8.  Erythropoietin regulates tumour growth of human malignancies.

Authors:  Yoshiko Yasuda; Yoshihiko Fujita; Takuya Matsuo; Satoshi Koinuma; Satoshi Hara; Akira Tazaki; Mie Onozaki; Mitsuhiro Hashimoto; Terunaga Musha; Kazuhiro Ogawa; Hiroyoshi Fujita; Yukio Nakamura; Hitoshi Shiozaki; Hiroshi Utsumi
Journal:  Carcinogenesis       Date:  2003-04-24       Impact factor: 4.944

9.  Prognostic significance of erythropoietin expression in human endometrial carcinoma.

Authors:  Geza Acs; Xiaowei Xu; Christina Chu; Peter Acs; Ajay Verma
Journal:  Cancer       Date:  2004-06-01       Impact factor: 6.860

10.  Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality.

Authors:  Gabriela Westphal; Ellen Niederberger; Christoph Blum; Yoram Wollman; Tobias A Knoch; Wolfgang Rebel; Jürgen Debus; Eckhard Friedrich
Journal:  Tumori       Date:  2002 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.